Biopharma bites: Remix’s reverse merger, Absci’s raise, ADC’s layoffs, and a new R&D head for Lundbeck

You’re leaving the Absci website. This link is provided for your convenience, but the content is the sole responsibility of its owner. Do you want to continue?